Results 131 to 140 of about 3,887,212 (164)

Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy. [PDF]

PLoS One
Frisch A, Kahn J, Collettini F, Steinhagen P, Fehrenbach U, Gebauer B, Amthauer H, Schatka I, Herzler P, Wieners G, Lüdemann WM.   +10 more
europepmc   +1 more source

Dosimetry in ¹⁷⁷Lu-PRRT for Neuroendocrine Tumors: Current Concepts, Clinical Relevance and Future Perspectives. [PDF]

J Clin Med
Poniatowska-Roszkowska ME, Troschke T, Birkenfeld B, Piwowarska-Bilska H.   +3 more
europepmc   +1 more source

Optimization of Gravity Infusion Protocols for ¹⁷⁷Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy. [PDF]

Pharmaceutics
Grasso S, Varallo A, Gaudieri V, Klain M, Pastore R, Arena S, Oliviero C, Buono M, Manzi D, Schiano R, Nappi C, Totaro P, Bonifacio RR, Cuocolo A, Clemente S.   +14 more
europepmc   +1 more source

Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response. [PDF]

Endocr Relat Cancer
Boehm E, Flynn A, Caneborg A, Hatzimihalis A, Hogg A, Waldeck K, Jackett L, Prall OWJ, Mitchell C, Kong G, Michael M, Akhurst T, Thomson BNJ, Murray WK, Chin K, Lawrence B, Print CG, Vissers JHA, Grimmond SM, Tothill RW, Hicks RJ.   +20 more
europepmc   +1 more source

The Evolving Role of Somatostatin Receptor PET/CT in Medullary Thyroid Carcinoma: An Updated Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Tasevski S, Imperiale A, Treglia G, Albano D.   +3 more
europepmc   +1 more source

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE? [PDF]

Oncologist
López-Robles J, Mitjavila M, Jimenez-Fonseca P, Marín-Melero I, Belló P, Pubul V, Garcia-Burillo A, Hernando J, Llana B, Ardila J, Arbizu J, Valverde R, Velasco M, Castellón M, Alonso-Gordoa T, García-Cañamaque L, Cano JM, Tabuenca MJ, Riesco MC, Custodio AB, Piñeiro A, Balaguer-Muñoz D, Nevares M, Carmona-Bayonas A.   +23 more
europepmc   +1 more source

Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

JCO Precis Oncol
Bogdani C, Karimi A, Li R, Atkinson EC, Oberstein PE, Siolas D.   +5 more
europepmc   +1 more source

Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges. [PDF]

Front Pharmacol
Shi W, Zhang L, Feng X, Liu J, Li X, Dong X, Li-Ann Wong A, Chen X, Wang L, Goh BC.   +9 more
europepmc   +1 more source

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Iizuka T, Kobayashi N, Wild D, Kaul F, Suzuki H, Maehara K, Okubo N, Tsuyuki S, Takano S, Kurita Y, Yoneda M, Ichikawa Y.   +11 more
europepmc   +1 more source

Theranostics in Radiation Medicine: Integrating Radiopharmaceutical Therapy and External-Beam Radiotherapy. [PDF]

J Clin Med
Srinivasan S, Moore JA, Han-Oh S.
europepmc   +1 more source